Form 4: Artiva Biotherapeutics Director, Daniel G. Baker, Acquires 27,500 Stock Options

Director Daniel G. Baker acquired 27,500 stock options in Artiva Biotherapeutics, Inc. on January 28, 2025, according to a Form 4 filing.

Summary

• On January 28, 2025, Daniel G. Baker, a director of Artiva Biotherapeutics, Inc., acquired 27,500 stock options.
• The options have an exercise price of $5.56.
• One-third of the shares vested immediately, with the remaining shares vesting monthly over the next two years.
• The options expire on January 27, 2035.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction filing. The acquisition of options by a director is generally viewed as a positive, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates